Adapalene gel 0.1% is better tolerated than tretinoin gel 0.025% among healthy volunteers of various ethnic origins

Background: The efficacious acne treatment adapalene gel 0.1% is significantly less irritating than tretinoin of various concentrations and formulations, according to several clinical studies conducted predominantly in Caucasian patients. Objectives: To confirm the lower irritation potential of adap...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of dermatological treatment Vol. 20; no. 5; pp. 282 - 288
Main Authors: Leok Goh, Chee, Tang, Mark B.Y., Briantais, Philippe, Kaoukhov, Alexandre, Soto, Pascale
Format: Journal Article
Language:English
Published: Oslo Informa UK Ltd 2009
Taylor & Francis
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Background: The efficacious acne treatment adapalene gel 0.1% is significantly less irritating than tretinoin of various concentrations and formulations, according to several clinical studies conducted predominantly in Caucasian patients. Objectives: To confirm the lower irritation potential of adapalene gel 0.1% compared to tretinoin gel 0.025% among volunteers of various ethnic origins and to explore the difference in the irritant susceptibility among ethnic groups. Methods: The study was a single-centre, randomized, investigator-masked and intra-individual comparison. Healthy volunteers applied adapalene and tretinoin daily to the face for 21 days and to the forearms for 4 days, and were then evaluated for the level of irritation. Results: The irritation potential of adapalene gel 0.1% was significantly lower than that of tretinoin gel 0.025% in all tolerability assessments, irrespective of the volunteers' ethnic origins. The between-treatment differences were similar among various ethnic groups. Statistically significant but small inter-ethnicity differences were observed in the evaluation of facial signs, with Caucasians being less susceptible than Chinese, Asian Indians and Malays. Conclusion: Adapalene gel 0.1% was significantly better tolerated than tretinoin gel 0.025% among various ethnic groups. The patients' ethnic origins had no impact on the difference between adapalene and tretinoin treatments in terms of tolerability.
AbstractList Background: The efficacious acne treatment adapalene gel 0.1% is significantly less irritating than tretinoin of various concentrations and formulations, according to several clinical studies conducted predominantly in Caucasian patients. Objectives: To confirm the lower irritation potential of adapalene gel 0.1% compared to tretinoin gel 0.025% among volunteers of various ethnic origins and to explore the difference in the irritant susceptibility among ethnic groups. Methods: The study was a single-centre, randomized, investigator-masked and intra-individual comparison. Healthy volunteers applied adapalene and tretinoin daily to the face for 21 days and to the forearms for 4 days, and were then evaluated for the level of irritation. Results: The irritation potential of adapalene gel 0.1% was significantly lower than that of tretinoin gel 0.025% in all tolerability assessments, irrespective of the volunteers' ethnic origins. The between-treatment differences were similar among various ethnic groups. Statistically significant but small inter-ethnicity differences were observed in the evaluation of facial signs, with Caucasians being less susceptible than Chinese, Asian Indians and Malays. Conclusion: Adapalene gel 0.1% was significantly better tolerated than tretinoin gel 0.025% among various ethnic groups. The patients' ethnic origins had no impact on the difference between adapalene and tretinoin treatments in terms of tolerability.
BACKGROUNDThe efficacious acne treatment adapalene gel 0.1% is significantly less irritating than tretinoin of various concentrations and formulations, according to several clinical studies conducted predominantly in Caucasian patients.OBJECTIVESTo confirm the lower irritation potential of adapalene gel 0.1% compared to tretinoin gel 0.025% among volunteers of various ethnic origins and to explore the difference in the irritant susceptibility among ethnic groups.METHODSThe study was a single-centre, randomized, investigator-masked and intra-individual comparison. Healthy volunteers applied adapalene and tretinoin daily to the face for 21 days and to the forearms for 4 days, and were then evaluated for the level of irritation.RESULTSThe irritation potential of adapalene gel 0.1% was significantly lower than that of tretinoin gel 0.025% in all tolerability assessments, irrespective of the volunteers' ethnic origins. The between-treatment differences were similar among various ethnic groups. Statistically significant but small inter-ethnicity differences were observed in the evaluation of facial signs, with Caucasians being less susceptible than Chinese, Asian Indians and Malays.CONCLUSIONAdapalene gel 0.1% was significantly better tolerated than tretinoin gel 0.025% among various ethnic groups. The patients' ethnic origins had no impact on the difference between adapalene and tretinoin treatments in terms of tolerability.
The efficacious acne treatment adapalene gel 0.1% is significantly less irritating than tretinoin of various concentrations and formulations, according to several clinical studies conducted predominantly in Caucasian patients. To confirm the lower irritation potential of adapalene gel 0.1% compared to tretinoin gel 0.025% among volunteers of various ethnic origins and to explore the difference in the irritant susceptibility among ethnic groups. The study was a single-centre, randomized, investigator-masked and intra-individual comparison. Healthy volunteers applied adapalene and tretinoin daily to the face for 21 days and to the forearms for 4 days, and were then evaluated for the level of irritation. The irritation potential of adapalene gel 0.1% was significantly lower than that of tretinoin gel 0.025% in all tolerability assessments, irrespective of the volunteers' ethnic origins. The between-treatment differences were similar among various ethnic groups. Statistically significant but small inter-ethnicity differences were observed in the evaluation of facial signs, with Caucasians being less susceptible than Chinese, Asian Indians and Malays. Adapalene gel 0.1% was significantly better tolerated than tretinoin gel 0.025% among various ethnic groups. The patients' ethnic origins had no impact on the difference between adapalene and tretinoin treatments in terms of tolerability.
Author Soto, Pascale
Tang, Mark B.Y.
Leok Goh, Chee
Kaoukhov, Alexandre
Briantais, Philippe
Author_xml – sequence: 1
  givenname: Chee
  surname: Leok Goh
  fullname: Leok Goh, Chee
  email: clgoh@nsc.gov.sg
  organization: 1National Skin Centre, Singapore
– sequence: 2
  givenname: Mark B.Y.
  surname: Tang
  fullname: Tang, Mark B.Y.
  email: clgoh@nsc.gov.sg
  organization: 1National Skin Centre, Singapore
– sequence: 3
  givenname: Philippe
  surname: Briantais
  fullname: Briantais, Philippe
  email: clgoh@nsc.gov.sg
  organization: 1National Skin Centre, Singapore
– sequence: 4
  givenname: Alexandre
  surname: Kaoukhov
  fullname: Kaoukhov, Alexandre
  email: clgoh@nsc.gov.sg
  organization: 1National Skin Centre, Singapore
– sequence: 5
  givenname: Pascale
  surname: Soto
  fullname: Soto, Pascale
  email: clgoh@nsc.gov.sg
  organization: 1National Skin Centre, Singapore
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21991024$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/19634042$$D View this record in MEDLINE/PubMed
BookMark eNp9kU9rFDEYh4NU7Lb6AbxILktPo_kzSSbopZSqhYIXPQ_ZmTe7KZlkTTKV_fZm2VGRQk-B5Hl-vO8vF-gsxAAIvaXkPSUd-UC0aKXkRBOmJKeyfYFWtFW0oUrwM7Q6vjcVaM_RRc4PhFAuSfcKnVNdL0nLVihfj2ZvPATAW_C4Bq-xy3gDpUDCJXpIpsCIy84EXBIUF6ILC0uYWGMzxbDFOzC-7A74Mfo5FICUcbT40SQX54yh7IIbcExu60J-jV5a4zO8Wc5L9OPz7febr839ty93N9f3zdByURo1sFZbqa0iVjKhWDdKRixnincb3YGWwJSWQoxWUSGlJdWQTFNOxCg6zS_R1Sl3n-LPGXLpJ5cH8N4EqFP1inPBdNeKStITOaSYcwLb75ObTDr0lPTHqvsnVVfn3ZI-byYY_xlLtxVYL4DJg_E2mTC4_JdjVGtK2DHo04lzwcY0mV8x-bEv5uBj-iPx5-b4-J9--onBJOgf4pxCbfiZLX4DQ-mqvg
CitedBy_id crossref_primary_10_1111_dth_12574
crossref_primary_10_1111_cod_13292
crossref_primary_10_4103_0974_2077_184043
crossref_primary_10_1007_s13555_022_00788_w
crossref_primary_10_1159_000444682
crossref_primary_10_1007_s13555_023_00943_x
crossref_primary_10_1080_14656566_2021_1990263
crossref_primary_10_1111_jocd_15662
crossref_primary_10_1093_ced_llad371
crossref_primary_10_1111_jocd_12031
crossref_primary_10_1177_1203475415591117
crossref_primary_10_1007_s13770_012_1088_z
crossref_primary_10_3109_09546634_2012_661037
crossref_primary_10_1111_1346_8138_14314
Cites_doi 10.1016/S0733-8635(03)00081-0
10.1046/j.1365-2133.1998.1390s2023.x
10.1046/j.1365-2133.1998.1390s2017.x
10.1016/S0190-9622(97)70051-3
10.1016/S0190-9622(97)70056-2
10.1034/j.1600-0536.2001.045002075.x
10.1111/j.1600-0536.1996.tb02141.x
10.1111/1523-1747.ep12323445
10.1111/j.1600-0536.1993.tb03534.x
10.1046/j.1365-2133.1998.1390s2048.x
10.1111/j.1365-2133.1993.tb03163.x
10.1046/j.1365-2133.1998.1390s2034.x
10.1067/mjd.2002.120791
10.1016/S0190-9622(97)70054-9
10.1046/j.1365-2133.1998.1390s2026.x
10.1067/mjd.2002.120790
10.1111/j.1600-0536.1998.tb05658.x
10.1111/j.1396-0296.2004.04019.x
10.1046/j.1365-2133.1998.1390s2041.x
10.1111/j.1600-0536.1999.tb06229.x
ContentType Journal Article
Copyright 2009 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2009
2009 INIST-CNRS
Copyright_xml – notice: 2009 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2009
– notice: 2009 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1080/09546630902763164
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-1753
EndPage 288
ExternalDocumentID 10_1080_09546630902763164
19634042
21991024
376486
Genre Original Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
00X
03L
0BK
0R~
0YH
29K
36B
4.4
53G
5GY
5VS
AAJNR
AALIY
AALUX
AAMIU
AAPUL
AAPXX
AAQRR
ABBKH
ABDBF
ABEIZ
ABLKL
ABPTK
ABUPF
ABWCV
ABZEW
ACENM
ACFUF
ACGEJ
ACGFS
ACKZS
ACLSK
ADCVX
ADFCX
ADFOM
ADFZZ
ADRBQ
ADXPE
AECIN
AEIIZ
AENEX
AEOZL
AEYQI
AFKVX
AFLEI
AFWLO
AGDLA
AGFJD
AGRBW
AIJEM
AIRBT
AJVHN
AJWEG
AKBVH
ALIIL
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AMDAE
AWYRJ
BABNJ
BLEHA
BOHLJ
BRMBE
CAG
CCCUG
COF
CS3
CYYVM
CZDIS
D-I
DKSSO
DRXRE
DU5
DWTOO
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
GROUPED_DOAJ
H13
HZ~
JENTW
KRBQP
KSSTO
KWAYT
KYCEM
LJTGL
M44
M4Z
O9-
P2P
QQXMO
RNANH
RVRKI
SV3
TFDNU
TFL
TFW
TUS
UEQFS
V1S
~1N
ABXYU
IQODW
AAORF
ABJNI
ABLIJ
AGYJP
ALYBC
CGR
CUY
CVF
ECM
EIF
NPM
NUSFT
TBQAZ
TDBHL
TERGH
TUROJ
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c435t-7c249f69f70f625728d620f32738b98e96e279655df71566f07c26291305d5893
ISSN 0954-6634
IngestDate Fri Oct 25 01:54:12 EDT 2024
Fri Nov 22 00:17:21 EST 2024
Tue Oct 15 23:38:51 EDT 2024
Sun Oct 22 16:04:13 EDT 2023
Tue Jun 13 19:30:20 EDT 2023
Wed Jun 21 01:44:02 EDT 2023
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Antineoplastic agent
Human
Skin disease
Healthy subject
Adapalene
Toxicity
Treatment efficiency
irritation potential
Retinoid
Ethnic group
Colloidal gel
ethnic groups
Secondary effect
Antiacneic agent
Comparative study
Irritation
Tretinoin
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c435t-7c249f69f70f625728d620f32738b98e96e279655df71566f07c26291305d5893
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
PMID 19634042
PQID 733529845
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_733529845
pubmed_primary_19634042
pascalfrancis_primary_21991024
crossref_primary_10_1080_09546630902763164
informahealthcare_journals_10_1080_09546630902763164
informaworld_taylorfrancis_310_1080_09546630902763164
PublicationCentury 2000
PublicationDate 20090000
1/1/2009
2009
2009-00-00
2009-01-01
20090101
PublicationDateYYYYMMDD 2009-01-01
PublicationDate_xml – year: 2009
  text: 20090000
PublicationDecade 2000
PublicationPlace Oslo
PublicationPlace_xml – name: Oslo
– name: England
PublicationTitle The Journal of dermatological treatment
PublicationTitleAlternate J Dermatolog Treat
PublicationYear 2009
Publisher Informa UK Ltd
Taylor & Francis
Publisher_xml – name: Informa UK Ltd
– name: Taylor & Francis
References Dunlap FE (CIT0011) 1998; 139
Kang S (CIT0006) 1995; 105
Ellis CN (CIT0014) 1998; 139
Cunliffe WJ (CIT0015) 1998; 139
Grosshans E (CIT0012) 1998; 139
Judge MR (CIT0021) 1996; 34
Robinson MK (CIT0018) 1999; 41
Verschoore M (CIT0007) 1993; 11
CIT0019
Taylor SC (CIT0003) 2002; 46
Halder RM (CIT0001) 1983; 32
Cunliffe WJ (CIT0010) 1997; 36
CIT0023
CIT0022
Cunliffe WJ (CIT0016) 2002; 12
Goh CL (CIT0002) 1994; 11
Dunlap FE (CIT0017) 1998; 139
Basketter DA (CIT0024) 1993; 29
Verschoore M (CIT0008) 1997; 36
CIT0025
Richards GM (CIT0020) 2003; 21
CIT0004
Callender VD (CIT0005) 2005; 76
CIT0009
Galvin SA (CIT0013) 1998; 139
References_xml – volume: 21
  start-page: 595
  year: 2003
  ident: CIT0020
  publication-title: Dermatol Clin.
  doi: 10.1016/S0733-8635(03)00081-0
  contributor:
    fullname: Richards GM
– volume: 76
  start-page: 19
  year: 2005
  ident: CIT0005
  publication-title: Cutis.
  contributor:
    fullname: Callender VD
– volume: 139
  start-page: 23
  issue: 52
  year: 1998
  ident: CIT0017
  publication-title: Br J Dermatol.
  doi: 10.1046/j.1365-2133.1998.1390s2023.x
  contributor:
    fullname: Dunlap FE
– volume: 139
  start-page: 17
  issue: 52
  year: 1998
  ident: CIT0011
  publication-title: Br J Dermatol.
  doi: 10.1046/j.1365-2133.1998.1390s2017.x
  contributor:
    fullname: Dunlap FE
– volume: 36
  start-page: S104
  issue: 6
  year: 1997
  ident: CIT0008
  publication-title: J Am Acad Dermatol.
  doi: 10.1016/S0190-9622(97)70051-3
  contributor:
    fullname: Verschoore M
– volume: 36
  start-page: S126
  issue: 6
  year: 1997
  ident: CIT0010
  publication-title: J Am Acad Dermatol.
  doi: 10.1016/S0190-9622(97)70056-2
  contributor:
    fullname: Cunliffe WJ
– ident: CIT0022
  doi: 10.1034/j.1600-0536.2001.045002075.x
– volume: 34
  start-page: 115
  year: 1996
  ident: CIT0021
  publication-title: Contact Dermatitis.
  doi: 10.1111/j.1600-0536.1996.tb02141.x
  contributor:
    fullname: Judge MR
– volume: 105
  start-page: 549
  year: 1995
  ident: CIT0006
  publication-title: J Invest Dermatol.
  doi: 10.1111/1523-1747.ep12323445
  contributor:
    fullname: Kang S
– volume: 11
  start-page: 107
  year: 1993
  ident: CIT0007
  publication-title: Dermatol Ther.
  contributor:
    fullname: Verschoore M
– volume: 11
  start-page: 15
  year: 1994
  ident: CIT0002
  publication-title: Pediatr Dermatol.
  contributor:
    fullname: Goh CL
– volume: 29
  start-page: 185
  year: 1993
  ident: CIT0024
  publication-title: Contact Dermatitis.
  doi: 10.1111/j.1600-0536.1993.tb03534.x
  contributor:
    fullname: Basketter DA
– volume: 139
  start-page: 48
  issue: 52
  year: 1998
  ident: CIT0015
  publication-title: Br J Dermatol.
  doi: 10.1046/j.1365-2133.1998.1390s2048.x
  contributor:
    fullname: Cunliffe WJ
– volume: 12
  start-page: 350
  year: 2002
  ident: CIT0016
  publication-title: Eur J Dermatol.
  contributor:
    fullname: Cunliffe WJ
– ident: CIT0023
  doi: 10.1111/j.1365-2133.1993.tb03163.x
– volume: 139
  start-page: 34
  issue: 52
  year: 1998
  ident: CIT0013
  publication-title: Br J Dermatol.
  doi: 10.1046/j.1365-2133.1998.1390s2034.x
  contributor:
    fullname: Galvin SA
– volume: 46
  start-page: S98
  year: 2002
  ident: CIT0003
  publication-title: J Am Acad Dermatol.
  doi: 10.1067/mjd.2002.120791
  contributor:
    fullname: Taylor SC
– ident: CIT0009
  doi: 10.1016/S0190-9622(97)70054-9
– volume: 139
  start-page: 26
  issue: 52
  year: 1998
  ident: CIT0012
  publication-title: Br J Dermatol.
  doi: 10.1046/j.1365-2133.1998.1390s2026.x
  contributor:
    fullname: Grosshans E
– ident: CIT0019
  doi: 10.1067/mjd.2002.120790
– volume: 32
  start-page: 388
  year: 1983
  ident: CIT0001
  publication-title: Cutis.
  contributor:
    fullname: Halder RM
– ident: CIT0025
  doi: 10.1111/j.1600-0536.1998.tb05658.x
– ident: CIT0004
  doi: 10.1111/j.1396-0296.2004.04019.x
– volume: 139
  start-page: 41
  issue: 52
  year: 1998
  ident: CIT0014
  publication-title: Br J Dermatol.
  doi: 10.1046/j.1365-2133.1998.1390s2041.x
  contributor:
    fullname: Ellis CN
– volume: 41
  start-page: 65
  year: 1999
  ident: CIT0018
  publication-title: Contact Dermatitis.
  doi: 10.1111/j.1600-0536.1999.tb06229.x
  contributor:
    fullname: Robinson MK
SSID ssj0013608
Score 1.9527136
Snippet Background: The efficacious acne treatment adapalene gel 0.1% is significantly less irritating than tretinoin of various concentrations and formulations,...
The efficacious acne treatment adapalene gel 0.1% is significantly less irritating than tretinoin of various concentrations and formulations, according to...
BACKGROUNDThe efficacious acne treatment adapalene gel 0.1% is significantly less irritating than tretinoin of various concentrations and formulations,...
SourceID proquest
crossref
pubmed
pascalfrancis
informaworld
informahealthcare
SourceType Aggregation Database
Index Database
Publisher
StartPage 282
SubjectTerms Adapalene
Administration, Cutaneous
Adolescent
Adult
Aged
Biological and medical sciences
Dermatologic Agents - administration & dosage
Dermatologic Agents - adverse effects
Dermatology
ethnic groups
Gels
Humans
irritation potential
Medical sciences
Middle Aged
Naphthalenes - administration & dosage
Naphthalenes - adverse effects
Pharmacology. Drug treatments
Single-Blind Method
Skin Diseases - chemically induced
Skin Diseases - ethnology
Skin Diseases - pathology
Skin involvement in other diseases. Miscellaneous. General aspects
Skin Irritancy Tests
Skin, nail, hair, dermoskeleton
tretinoin
Tretinoin - administration & dosage
Tretinoin - adverse effects
Young Adult
Title Adapalene gel 0.1% is better tolerated than tretinoin gel 0.025% among healthy volunteers of various ethnic origins
URI https://www.tandfonline.com/doi/abs/10.1080/09546630902763164
https://www.ncbi.nlm.nih.gov/pubmed/19634042
https://search.proquest.com/docview/733529845
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1La9wwEBabDZReSvrePoIO7aXGwdZKsn3cptsGQnLpBtqT8UPqhgQ71N5A_31nLFl2NiS0hV7MYiw_NN9-MxrNg5B3YazzIC6EHxUi8LkOE-DBEsiwZHOR5JInXTufo6_R6bf405IvJ5O-ls5w7r9KGs6BrDFz9i-k7W4KJ-A3yByOIHU4_pHcFyWoP1AlyvuhLj0gq_dMYNfyvMvbAVPzEssoKwybhL92i0mMVX1e2asDbFMkbAsikyP5y0MGg_nHVF8wLa9hdY1xs6pdY_Mc01mrGRu5Q7pZZ-iWSP6tI1kX2j7EAtUX3pfa7PWslUPayrqyMZ3I-3jw_WBwHQCm28xURzAeoSs36jirNxfr-nqUvWPje3vfxsCdfS7W2fEousl4LbkPRpLxQSjD2aBffSw4OiZ1FozAK8YMbXodWWXPTE_BW3rEBl7C0-BhGLoKNBxKPihNF8oY9jVWt6_dIbsMyI9Nye7icHl6Muxtya5PovuUfq8dK75v3-SGtbRna-muXWTgVn1dDOzNGhClNk1Z7l41ddbTao88smigC4PXx2SiqifkwYkN7HhKGgdbCkCkCFt63lADWupASxG01IHWXougpR1kqYUsHSBLa00tZKmBLLWQfUbOPi9Xh0e-7QfiF2DUt0AnjCdaJjoKNCzbIxaXkgV6jtlleRKrRCqYcSlEqSN0S-gARkiWgJkmSgGG-XMyrepKvSS0kDKbKyHzLBK8KHnONMszxnWpg0CFfEY-9POeXpmyL-mdkp4RfksyqaWE5r5hYiy8tO1cdFZ06fyecfs3pOxekGEYI9jcM0J7saegLHAHMKsUTHMaYYZlEnMxIy8MHIavA03MQYO_-rePeU0emn1WdE6-IdP250a9JTtNudm3-P8NYujiMg
link.rule.ids 315,782,786,4028,27932,27933,27934,59868,60657,61275,61456
linkProvider Taylor & Francis
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB61Wwm40FJeS2mZA70gRWS9thNfKq3KVlvR3QtF4hYlsU1XqhJEskj9953Joy9KD_SeiWyPZ-Ybzwvg4yj2WRjnKohyFQbSjwzpQUvK0IqxMpmWphnnM_sWLX7EX6bcJuegr4XhtEr2oX3bKKLR1Szc_Bjdp8R9JlggyVJySiGJBwH-ddjgPuPxADYmh9PF_DqOoJuZdEwQEIXs45r3_eSWZdrq-paeXWVh3ellykmUaUXn6NsBGP9GqI2lOtp87B634HmHUXHSXqoXsOaKbXgy76LwL6GaWDKxZK4c_nTnSL_ax2WFWVMZhHV5zo2anUV-lceayySLcll03xL62cdmxBG2u75A1pDEXwKiWHr8Q957uarQ1WfFMsd2clf1Cr4fTU8PZ0E3vCHICYHVxHty7Lw2Pgo9-ViRiK0WoR9zKVBmYme0E5HRSlkfsQ_pQ6LQwpBNVVYRinoNg6Is3FvAXOt07JTO0kjJ3MpMeJGlQnrrw9CN5BA-9YxLfrU9OpJR3_r07jEOQf7F2qST2-ohMnWT-0ndvKd0vE_GD9Dt3bomVwsUnHNGAGkI2N-bhCSbwzVp4eiYk4jL4Uws1RDetPfpenekNiWp23f_uaoP8HR2Oj9JTo4XX3fgWRsh42el9zCof6_cLqxXdrXXSdMlEpkXrg
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB4VkFAvhb6XAp1DuVSKmvXaTnzgsIJdgSirSm2l3qIktmEllKAmi8S_ZyYPKBQ4wD0T2R7PzDeeF8CXYeyzMM5VEOUqDKQfGtKDlpShFSNlMi1NM87n4Gc0-xPvT7hNzm5fC8NplexD-7ZRRKOrWbjPre8z4r4RKpBkKDmjkKSD8P4SrBAOV-R7rYz3JrPjmzCCbkbSMUFAFLIPa973k1uGab1rW3p6nYR1p5Up51CmFR2jb-dfPAxQG0M1XXvmFtfhVYdQcdxeqdfwwhVvYPW4i8G_hWpsycCSsXJ44s6QfrWD8wqzpi4I6_KM2zQ7i_wmjzUXSRblvOi-Jeyzg82AI2w3fYmsH4m7BEOx9HhBvnu5qNDVp8U8x3ZuV_UOfk8nv_YOgm50Q5AT_qqJ8-TWeW18FHrysCIRWy1CP-JCoMzEzmgnIqOVsj5iD9KHRKGFIYuqrCIM9R6Wi7JwHwFzrdORUzpLIyVzKzPhRZYK6a0PQzeUA_ja8y05bzt0JMO-8endYxyA_I-zSSe11WNk6l_mJ3XzmtKxPhk9Qrd965ZcL1BwxhnBowFgf20SkmsO1qSFo2NOIi6GM7FUA_jQXqeb3ZHSlKRsN564qs-w-mN_mnw_nB19gpdteIzflDZhuf67cFuwVNnFdidLV32QFlI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adapalene+gel+0.1%25+is+better+tolerated+than+tretinoin+gel+0.025%25+among+healthy+volunteers+of+various+ethnic+origins&rft.jtitle=The+Journal+of+dermatological+treatment&rft.au=Leok+Goh%2C+Chee&rft.au=Tang%2C+Mark+B.Y.&rft.au=Briantais%2C+Philippe&rft.au=Kaoukhov%2C+Alexandre&rft.date=2009&rft.pub=Informa+UK+Ltd&rft.issn=0954-6634&rft.eissn=1471-1753&rft.volume=20&rft.issue=5&rft.spage=282&rft.epage=288&rft_id=info:doi/10.1080%2F09546630902763164&rft.externalDocID=10_1080_09546630902763164
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0954-6634&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0954-6634&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0954-6634&client=summon